A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer

Published:2009-04-18 Issue:6 Volume:64 Page:1181-1185
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Totani Yoshitaka,Saito Yuji,Hayashi Masamichi,Tada Toshihiko,Kohashi Yasuo,Mieno Yuki,Kato Atsushi,Imizu Hiromi,Yoneda Yukiko,Hoshino Tami,Uchiyama Yasuhiro,Takeuchi Yasuo,Okazawa Mitsushi,Sakakibara Hiroki

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-009-0981-1.pdf

Reference16 articles.

1. Greenlee RT, Murray T, Bolden S, Wingo PA (2000) Cancer statistics, 2000. CA Cancer J Clin 50:7–33

2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, Eastern Cooperative Oncology Group (2002) Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346(2):92–98

3. Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N, Giaccone G, European Organization for Research, Treatment of Cancer Lung Cancer Group (2003) Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group, EORTC 08975. J Clin Oncol 21(21):3909–3917

4. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18(10):2095–2103

5. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens: The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18(12):2354–2362

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II trial of daily S‐1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101;Thoracic Cancer;2023-08-17

2. S‐1 eliminates MDSCs and enhances the efficacy of PD ‐1 blockade via regulation of tumor‐derived Bv8 and S100A8 in thoracic tumor;Cancer Science;2022-11-11

3. Efficacy of S‐1 after pemetrexed in patients with non‐small cell lung cancer: A retrospective multi‐institutional analysis;Thoracic Cancer;2021-07-13

4. Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer;International Journal of Clinical Oncology;2020-11-07

5. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients;Respiratory Investigation;2020-07